SWK002 for tough-to-treat rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a new treatment called SWK002 for people with rheumatoid arthritis that hasn't improved after trying multiple medications. It aims to see if SWK002 can help when other treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have rheumatoid arthritis that did not get better with at least 2 different types of advanced medications.
- You have moderate to high disease activity despite treatment.
- You are on a stable dose of at least one standard rheumatoid arthritis drug for more than 4 weeks.
- You do not have active tuberculosis or serious infections.
- Your heart, kidneys, and liver are working well enough for the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new one-time IV treatment (BX-U001) for people with rheumatoid arthritis that hasn't improved with standard therapies. The goal is to check its safety and how well people tolerate it.
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This trial tests a new experimental antibody called GNC-038 for people with moderate to severe rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if targeting specific immune cells can reduce inflammation and improve symptoms.
This early-phase trial tests whether a new type of immune cell (CAR NK) can treat two conditions: antisynthetase antibody syndrome (a rare autoimmune disease) and rheumatoid arthritis. It's for people whose current treatments haven't worked well enough.
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.